MBX Biosciences Inc (NASDAQ: MBX)’s stock price has gone rise by 391055 in comparison to its previous close of 9.73, however, the company has experienced a 5.24% increase in its stock price over the last five trading days. globenewswire.com reported 2025-06-23 that CARMEL, Ind., June 23, 2025 (GLOBE NEWSWIRE) — MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the appointment of Andreas Moraitis, M.D.
Is It Worth Investing in MBX Biosciences Inc (NASDAQ: MBX) Right Now?
Analysts have differing opinions on the stock, with 3 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for MBX is 14.84M, and currently, short sellers hold a 31.98% ratio of that floaft. The average trading volume of MBX on June 25, 2025 was 286.33K shares.
MBX’s Market Performance
The stock of MBX Biosciences Inc (MBX) has seen a 5.24% increase in the past week, with a -11.67% drop in the past month, and a 35.92% gain in the past quarter. The volatility ratio for the week is 7.61%, and the volatility levels for the past 30 days are at 5.25% for MBX. The simple moving average for the past 20 days is -3.98% for MBX’s stock, with a -25.02% simple moving average for the past 200 days.
Analysts’ Opinion of MBX
Many brokerage firms have already submitted their reports for MBX stocks, with Citizens JMP repeating the rating for MBX by listing it as a “Mkt Outperform.” The predicted price for MBX in the upcoming period, according to Citizens JMP is $38 based on the research report published on April 10, 2025 of the current year 2025.
Stifel, on the other hand, stated in their research note that they expect to see MBX reach a price target of $40. The rating they have provided for MBX stocks is “Buy” according to the report published on October 08th, 2024.
JP Morgan gave a rating of “Overweight” to MBX, setting the target price at $30 in the report published on October 08th of the previous year.
MBX Trading at 3.16% from the 50-Day Moving Average
After a stumble in the market that brought MBX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -59.82% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MBX starting from Pescovitz Ora H., who purchase 7,693 shares at the price of $5.89 back on Apr 08 ’25. After this action, Pescovitz Ora H. now owns 24,329 shares of MBX Biosciences Inc, valued at $45,312 using the latest closing price.
GORDON CARL L, the Director of MBX Biosciences Inc, purchase 143,170 shares at $10.84 during a trade that took place back on Feb 18 ’25, which means that GORDON CARL L is holding 3,255,000 shares at $1,551,963 based on the most recent closing price.
Stock Fundamentals for MBX
The total capital return value is set at -0.35. Equity return is now at value -48.22, with -45.74 for asset returns.
Based on MBX Biosciences Inc (MBX), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -512.68.
Currently, EBITDA for the company is -67.95 million with net debt to EBITDA at 0.37. The liquidity ratio also appears to be rather interesting for investors as it stands at 23.31.
Conclusion
In a nutshell, MBX Biosciences Inc (MBX) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
